Work

Bortezomib to Treat the TEMPI Syndrome

Year: 2012

Type: article

Abstract: Telangiectasias, erythrocytosis, monoclonal gammopathy, perinephric-fluid collection, and intrapulmonary shunting are characteristic of the TEMPI syndrome. A case report documents improvement with bortezomib, a drug used in the treatment of myeloma.

Source: New England Journal of Medicine

DOI: 10.1056/nejmc1202649

Authors: Mary Kwok, Neha Korde, Ola Landgren

Institutions: University of Pittsburgh, Dartmouth Institute for Health Policy and Clinical Practice

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute